Milestone Pharmaceuticals (MIST) Receivables (2026)
Milestone Pharmaceuticals' (MIST) quarterly Receivables came in at $3.4 million in Q2 2026, up 13.73% quarter-over-quarter from $3.0 million in Q1 2026.
Powered by 
Analysis
Milestone Pharmaceuticals (MIST) Receivables (2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has reported Receivables for 1 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Milestone Pharmaceuticals | 146.32 Mn | -25.18 Mn | - | 3.45 Mn |